Other
Andrew Carr
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 4
3(100.0%)
3Total
Phase 4(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT02211690Phase 4Completed
The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis
Role: lead
NCT01715636Phase 4Completed
Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.
Role: lead
NCT01087840Phase 4Completed
Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men
Role: lead
All 3 trials loaded